Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer, KineMed In Diabetes Research Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Pfizer, KineMed In Diabetes Research Pact

Will utilize KineMed’s Dynamic Proteomics technology platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer and KineMed, Inc. have entered a non-exclusive research collaboration to advance novel approaches in metabolic disease, namely Type II Diabetes. KineMed will use its Dynamic Proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

“We are delighted to be collaborating with Pfizer in taking novel and innovative approaches, by targeting disease pathways that have previously remained undeveloped as drug targets,” said Dr. Scott Turner, executive vice president, R&D at KineMed. “We are using our translational platform to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics